Omni Bio Pharmaceutical, Inc. is an emerging biopharmaceutical company that has licensed therapies currently in development that have the potential to address large, unmet diseases and generate substantial commercialization potential. Our core strategy is based on licensing issued and pending patents that cover new uses for an existing FDA-approved drug, Alpha-1 antitrypsin (AAT). We intend to leverage sponsored research, collaborations with existing AAT manufacturers, and licensed patents for the development and commercialization of AAT in additional indications. AAT has a 20-year safety record as an approved treatment for emphysema in AAT-deficient patients (a market that is currently estimated at $400 million). We are currently evaluating AAT for the treatment of several diseases, including Type 1 diabetes, HIV, graft versus host disease (GVHD), influenza and other diseases, as well as a treatment for anthrax exposure. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, inflammation, biohazards, diabetes and transplant rejection.